KIT and intrahepatic cholangiocarcinoma: Future prospects for GI dysmotility intervention could involve strategies to augment SCF/c-Kit signaling, targeting VSICs, cellular transplantation of ICC cells or MSCs supported by ex vivo or genetic modifications to enhance their homing, engraftment, proliferation and function in the injured intestines.